{"name":"Visirna Therapeutics HK Limited","slug":"visirna-therapeutics-hk-limited","ticker":"","exchange":"","domain":"visirnahk.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VSA003","genericName":"VSA003","slug":"vsa003","indication":"Other","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebon","genericName":"Placebon","slug":"placebon","indication":"Generalized anxiety disorder","status":"phase_3"}]}],"pipeline":[{"name":"VSA003","genericName":"VSA003","slug":"vsa003","phase":"phase_3","mechanism":"VSA003 is an investigational therapeutic targeting viral or cellular mechanisms relevant to its indication in phase 3 development.","indications":[],"catalyst":""},{"name":"Placebon","genericName":"Placebon","slug":"placebon","phase":"phase_3","mechanism":"Placebon is a small molecule that targets the serotonin receptor.","indications":["Generalized anxiety disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQeU4wVGdpNWR3TWQ0SkVDZnh3eExnV1ZlbjhSQTc2M3ZQcWhvSHZ0MTU5aUg5SkxqRFRjMFNtU2V3RE0xX1hVOHNQMzdld1R4OUhfb2hTX1paYzJ4cDhjV3FSVkw1MlZnOEdIZk5yTzJRaGoyZldHT0FWU0RpYjUtVmwzVTkwcUR0YmlJSWRyM25BaEdxVm1kcnRETnR0a2taVjNRVVhtQ1pkeGc?oc=5","date":"2025-11-17","type":"pipeline","source":"Seeking Alpha","summary":"Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead (NASDAQ:ARWR) - Seeking Alpha","headline":"Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead (NASDAQ:ARWR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPMTB3NndsRzRKTlMzVi04eUtQUlpoMVJyXzJWdTlaYUZ3ejVIRXktS2NVQWpMcFJpdVR3blhOSkFxTDQ4TmZlbldTNk9PWHRVb1RrMVpYSWJHWnJHY3ZKUUhqVnprZ1JGM2dreUVHZ3EtQmJhaHp5NTVFa3ZpazBmU3BYRnpDcUtIYXBIcHBldmR6RFZTQ2FCMkFjR3FvTzNI?oc=5","date":"2025-08-04","type":"deal","source":"Pharmaceutical Executive","summary":"Sanofi Purchases $130 million Exclusive License for Plozasiran from Visirna Therapeutics - Pharmaceutical Executive","headline":"Sanofi Purchases $130 million Exclusive License for Plozasiran from Visirna Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPYVdDZFpWRzNFZmMwMGliY3lNeE5lUHEzY1ZoXzk2UDJJQXZnUlc4U2lBWFN5ZXd4NlZ1Sk9HellVNFNlOFNCZXpaeVZSWXdSRHVHTVhtd3dnVlpIZm92RHd0c2I1bHB6MEc1VUlIMG05Y1hrWEFzOUlyOGQyMVJjSVdINkdseUxxc08wcWhR?oc=5","date":"2025-08-04","type":"pipeline","source":"pharmaphorum","summary":"Sanofi grabs Chinese rights to Arrowhead rare disease drug - pharmaphorum","headline":"Sanofi grabs Chinese rights to Arrowhead rare disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxONllKM1Y4ZUFQU3p1ZzB2OHRZUFA4MHBUd1pGUV9qVEIzMTM1VEo4OS1KNk5rNmtneW1oRm1rWDNuS1RBZFBxMk1pcTltX1l0M0ZTVG5Vd01sVm1TQzg3Nkk4V241S1VGU1F0eHFxczk1a08tcy1mbnhac1hvZE5nS3JtRkExaFlsdFFPeHRoMDh1U0JRdG1LZTZfRUpxejNJRDVLYm5fY3pnVUUwblN0TXVzUWI2dzZuQlJyanN1RjNOekVzVnpR?oc=5","date":"2025-08-01","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Arro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQLTRQeERtd3hXRWt6eGk1YmVyN3hhTGl1WEs0RU9FdndRVlhTekh4S19ubGlqOEpDcVdFR1RfN3JtVmxYbmNsNGhDclk4RGZzTEw1alVNcGZRMGFnOFJmZUFkejlEY0pod3N6akdqa2dkS3VIUHJlUUJyZy1Nci1CR1RSZzh2LXhySmRXcl9uTmJJSUVQSVNMLS1mVzFyV0FEZE5vd19B?oc=5","date":"2022-04-25","type":"pipeline","source":"Fierce Biotech","summary":"Vivo Capital seeds new venture with $60M to take Arrowhead therapies to China - Fierce Biotech","headline":"Vivo Capital seeds new venture with $60M to take Arrowhead therapies to China","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}